natgillin/translations-raw huggingface dataset:
Physicians should refer to the individual prescribing information for these medicinal products. 
Pri predpisovanju morajo zdravniki upoštevati podatke za vsako posamezno zdravilo.
Lamivudine-TP and zidovudine-TP have selective inhibitory activity against HIV-1 and HIV-2 replication in vitro; lamivudine is also active against zidovudine-resistant clinical isolates of HIV. 
Lamivudin-TP in zidovudin-TP delujeta kot selektivna zaviralca in vitro replikacije virusov HIV-1 in
There is no evidence of added toxicity following concurrent administration of the two compounds. 
O povečanju toksičnosti zaradi sočasne uporabe obeh učinkovin ni podatkov.
Caution should be exercised when administering zidovudine to any patient (particularly obese women) with hepatomegaly, hepatitis or other known risk factors for liver disease and hepatic steatosis (including certain medicinal products and alcohol). 
hepatitisom ali z drugimi znanimi dejavniki tveganja za jetrno bolezen in jetrno steatozo (vključno z določenimi zdravil in alkoholom) je potrebna previdnost.
Lactic acidosis: Lactic acidosis usually associated with hepatomegaly and hepatic steatosis has been reported with the use of zidovudine. 
Laktacidoza: Pri uporabi zidovudina so poročali o laktacidozi, navadno v povezavi s hepatomegalijo in jetrno steatozo.
Combination therapy such as Lamivudine/Zidovudine Teva may cause other conditions to develop during HIV treatment. 
Kombinirano zdravljenje, ki vključuje zdravilo Lamivudin/zidovudin Teva, lahko med zdravljenjem okužbe s HIV povzroči nastanek drugih motenj.
Methadone dosage adjustment unlikely in majority of patients; occasionally methadone retitration may be required. 
Pri večini bolnikov prilagoditev odmerka metadona ni verjetna;
Renal impairment: Lamivudine and zidovudine concentrations are increased in patients with renal impairment due to decreased clearance. 
Oslabljeno delovanje ledvic: Zaradi manjšega očistka so koncentracije lamivudina in zidovudina pri bolnikih z oslabljenim delovanjem ledvic povečane.
White opaque HDPE containers with white opaque polyethylene child resistant screw cap with Aluminium seal. 
Neprozorne bele HDPE plastenke z neprozornim belim, za otroke varnim pokrovčkom na navoj in z aluminijastim pečatom.
Hepatic impairment: Limited data in patients with cirrhosis suggest that accumulation of zidovudine may occur in patients with hepatic impairment because of decreased glucuronidation. 
Jetrna okvara: Skopi podatki pri bolnikih s cirozo kažejo, da lahko manjši obseg glukuronidacije pri bolnikih z jetrno okvaro privede do kopičenja zidovudina.
If gastrointestinal intolerance occurs in patients weighing 21-30 kg, an alternative dosing schedule with one-half tablet taken thrice daily can be applied in attempt to improve tolerability. 
V primeru prebavnih težav bo pri bolnikih s telesno maso od 21 do 30 kg pri alternativnem režimu odmerjanja (to je polovica tablete trikrat na dan) prenašanje zdravila morda boljše.
Swallow Lamivudine/Zidovudine Teva tablets with some water. 
Tableto Lamivudin/zidovudin Teva pogoltnite celo z nekaj vode.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON - BLISTER PACK 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA - PRETISNI OMOT
Reproductive system and breast disorders Rare: Gynaecomastia 
Redki: pogosto uriniranje Motnje reprodukcije in dojk Redki: ginekomastija
• muscle weakness. 
• oslabelost mišic.
This loss of body fat has been shown to be not fully reversible after discontinuation of zidovudine. 
Izkazalo se je, da po prekinitvi zdravljenja z zidovidinom ta izguba telesnega maščevja ni v celoti ozdravljiva.
Atovaquone/Zidovudine (750 mg twice daily with food/200 mg thrice daily) 
atovakon/zidovudin (750 mg dvakrat na dan s hrano/200 mg trikrat na dan)
• inflammation of the pancreas (pancreatitis) 
• vnetje trebušne slinavke (pankreatitis),
Evidence from clinical studies shows that lamivudine plus zidovudine delays the emergence of zidovudine resistant isolates in individuals with no prior antiretroviral therapy. 
Izsledki kliničnih raziskav kažejo, da lamivudin skupaj z zidovudinom pri bolnikih, ki še niso bili deležni protiretrovirusne terapije, zakasni pojav izolatov, odpornih na zidovudin.
Zidovudine is primarily metabolised by UGT enzymes; co-administration of inducers or inhibitors of UGT enzymes could alter zidovudine exposure. 
Zidovudin se presnovi predvsem z encimi UGT; sočasna uporaba induktorjev ali zaviralcev encimov
The usual starting dose of Lamivudine/Zidovudine Teva is one half tablet (½) taken in the morning and one whole tablet taken in the evening. 
Običajni začetni odmerek zdravila Lamivudin/zidovudin Teva je polovica (½) tablete zjutraj in ena cela tableta zvečer.
Remember to tell your doctor or pharmacist if you begin taking a new medicine while you are taking Lamivudine/Zidovudine Teva. 
Zdravniku ali farmacevtu morate vedno povedati, če med zdravljenjem z zdravilom Lamivudin/zidovudin Teva začnete prejemati kakšno novo zdravilo.
Not everyone responds to treatment with Lamivudine/Zidovudine Teva in the same way. 
Na zdravilo Lamivudin/zidovudin Teva se ne odzovejo vsi bolniki enako.
Clarithromycin/Zidovudine (500 mg twice daily/100 mg every 4 hours) 
klaritromicin /zidovudin (500 mg dvakrat na dan/100 mg na 4 ure )
The extent of lamivudine and zidovudine absorption (AUC∞) and estimates of half-life following administration of lamivudine/zidovudine with food were similar when compared to fasting subjects, although the rates of absorption (Cmax, tmax) were slowed. 
Obseg absorpcije (AUC∞) lamivudina in zidovudina in ocene razpolovnih časov po aplikaciji zdravila Lamivudin/zidovudin Teva s hrano so bile podobne kakor pri aplikaciji na tešče,
Lamivudine/Zidovudine Teva is available in aluminium blisters or HDPE containers containing 60 tablets. 
Zdravilo Lamivudin/zidovudin Teva filmsko obložene tablete so na voljo v pretisnih omotih ali plastenkah, ki vsebujejo po 60 tablet.
Lamivudine/Zidovudine Teva can be taken with or without food. 
Lamivudin/zidovudin Teva vzame s hrano ali brez nje.
Studies in patients with renal impairment show lamivudine elimination is affected by renal dysfunction. 
Raziskave pri bolnikih z oslabljenim delovanjem ledvic so pokazale, da nenormalno delovanje ledvic vpliva na izločanje lamivudina.
Lamivudine/Zidovudine Teva can make you dizzy and have other side effects that make you less alert. 
Zdravilo Lamivudin/zidovudin Teva lahko povzroči omotičnost in tudi druge neželene učinke, ki vplivajo na zmanjšano pripravljenost.
Each film-coated tablet contains lamivudine 150 mg zidovudine 300 mg 
Ena filmsko obložena tableta vsebuje lamivudin 150 mg zidovudin 300 mg
Cssmax levels were 4.45 μM (1.19 μg/ml) following a dose of 120 mg zidovudine (in solution)/m2 body surface area and 7.7 μM (2.06 μg/ml) at 180 mg/m2 body surface area. 
Pri uporabi zidovudina (v obliki raztopine) v odmerku 120 mg/m telesne površine je bila največja koncentracija v stanju dinamičnega ravnovesja (Cssmax) 4,45 μM (1,19 μg/ml), pri uporabi zidovudina v odmerku 180 mg/m telesne površine pa 7,7
Zidovudine is contraindicated in patients with abnormally low neutrophil counts (<0.75 x 109/l), or abnormally low haemoglobin levels (<7.5 g/dl or 4.65 mmol/l). 
9/l) ali izredno nizkimi vrednostmi hemoglobina (<7,5 g/dl ali 4,65 mmol/l).
- The active substances are lamivudine 150 mg and zidovudine 300 mg. - The other ingredients are: Tablet core: Cellulose microcrystalline, sodium starch glycolate (Type A), sodium stearyl fumarate. 
- Druge pomožne snovi so: Jedro tablete; mikrokristalna celuloza, natrijev karboksimetilškrob (vrsta A), natrijev staril fumarat.
The usual starting dose of Lamivudine/Zidovudine Teva is one half tablet (½) taken in the morning and one half tablet (½) taken in the evening. 
Običajni začetni odmerek zdravila Lamivudin/zidovudin Teva je polovica (½) tablete zjutraj in polovica (½) tablete zvečer.
Zidovudine AUC ↑106% (UGT inhibition) 
AUC zidovudina ↑106% (zavrtje UGT)
Uncommon: Fever, generalised pain and asthenia Rare: Chills, chest pain and influenza-like syndrome 
Redki: mrzlica, bolečine v prsih in sindrom, podoben influenci
Zidovudine AUC ↓48% (UGT induction) 
AUC zidovudina ↓48% (indukcija UGT)
What Lamivudine/Zidovudine Teva looks like and contents of the pack 
Izgled zdravila Lamivudin/zidovudin Teva in vsebina pakiranja
People may be more likely to get this condition: 
Verjetnost za to motnjo je večja, pri bolnikih:
Combination therapy for HIV can also cause: • increased levels of lactic acid in the blood, which on rare occasions can lead to lactic acidosis. 
• povišane vrednosti mlečne kisline v krvi, kar v redkih primerih lahko povzroči laktacidozo.
As well as the side effects listed below for Lamivudine/Zidovudine Teva, other conditions can develop during combination therapy for HIV. 
Poleg neželenih učinkov zdravila Lamivudin/zidovudin Teva, ki so navedeni spodaj, se lahko med kombiniranim zdravljenjenjem okužbe s HIV pojavijo še druge motnje.
• amphotericin or co-trimoxazole, to treat fungal and bacterial infections 
• amfotericin ali kotrimoksazol za zdravljenje bakterijskih in glivičnih okužb;
Lamivudine has not shown any genotoxic activity in in vivo studies at doses that gave plasma concentrations up to 40-50 times higher than clinical plasma levels. 
Lamivudin pri odmerkih, ki so dali 40- do 50-krat večje plazemske koncentracije od terapevtskih, in vivo ni pokazal nobenega genotoksičnega delovanja.
A very rare side effect that may show up in blood tests is: • a failure of the bone marrow to produce new red or white blood cells (aplastic anaemia). 
• Pojavijo se lahko pri največ 1 od 10.000 bolnikov.nezmožnost kostnega mozga za tvorbo novih rdečih ali belih krvnih celic (aplastična anemija).
Tell your doctor if you are being treated with any of these. 
Zdravniku morate povedati, če se zdravite s katerimkoli od teh zdravil.
Some medicines interact with Lamivudine/Zidovudine Teva 
Nekatera zdravila medsebojno delujejo z zdravilom Lamivudin/zidovudin Teva
The clinical significance of these findings is unknown. 
Klinični pomen teh ugotovitev ni znan.
Rare: Cough 
Občasni: dispneja Redki: kašelj
Exacerbation of anaemia due to ribavirin has been reported when zidovudine is part of the regimen used to treat HIV although the exact mechanism remains to be elucidated. 
Opisano je bilo poslabšanje anemije zaradi ribavirina, če je bil zidovudin del sheme za zdravljenje
Rare side effects These may affect up to 1 in 1000 people: 
Pojavijo se lahko pri največ 1 od 1.000 bolnikov:
Weight and metabolic parameters: An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. 
Telesna masa in presnovni parametri: Med protiretrovirusnim zdravljenjem se lahko poveča telesna masa ter zviša koncentracija lipidov in glukoze v krvi.
Rare side effects that may show up in blood tests are: 
Redki neželeni učinki, ki se lahko pokažejo v preiskavah krvi, so:
Rare: Insomnia, paraesthesiae, somnolence, loss of mental acuity, convulsions 
Redki: nespečnost, parestezija, dremavost, zmanjšana sposobnost koncentracije, krči
• general feeling of being unwell 
• splošno slabo počutje,
However, as dosage adjustments for zidovudine may be necessary, it is recommended that separate preparations of lamivudine and zidovudine be administered to patients with severe hepatic impairment. 
Ker bo verjetno potrebno odmerek zidovudina prilagoditi, je pri bolnikih s hudo jetrno okvaro priporočljivo uporabljati lamivudin in zidovudin kot samostojni zdravili.
Opportunistic infections: Patients receiving Lamivudine/Zidovudine Teva or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection. 
Oportunistične okužbe: Ker se pri bolnikih, ki se zdravijo z zdravilom Lamivudin/zidovudin Teva ali s katerim koli drugim protiretrovirusnim zdravljenjem, še vedno lahko pojavijo oportunistične okužbe in drugi zapleti vezani na okužbo z virusom HIV, morajo bolniki ostati pod skrbnim kliničnim nadzorom zdravnikov z izkušnjami pri zdravljenju okužbe z virusom HIV.
Lamivudine/Zidovudine Teva 150 mg/300 mg film-coated tablets 
Lamivudin/zidovudin Teva 150 mg/300 mg filmsko obložene tablete
Rare: Oral mucosa pigmentation, taste perversion and dyspepsia. 
Občasni: napenjanje Redki: pigmentacija ustne sluznice, motnje v okušanju in dispepsija,pankreatitis
Interactions involving binding site displacement are not anticipated with Lamivudine/Zidovudine Teva. 
Interakcije, ki bi obsegale izpodrivanje z vezavnih mest pri zdravilu Lamivudin/zidovudin Teva, niso pričakovane.
Separate administration of Lamivudine/Zidovudine Teva and clarithromycin by at least 2 hours 
Med uporabo zdravila Lamivudin/zidovudin Teva in uporabo klaritromicina morata miniti vsaj 2 uri.
Marketing Authorisation Holder and Manufacturer Marketing Autnorisation Holder 
Imetnik dovoljenja za promet z zdravilom in izdelovalec Imetnik dovoljenja za promet
• a low red blood cell count (anaemia) or low white blood cell count (neutropenia or leucopenia) 
• zmanjšano število rdečih krvnih celic (anemija) ali zmanjšano število belih krvnih celic
An uncommon side effect that may show up in blood test is: 
Občasni neželeni učinek, ki se lahko pokaže v preiskavah krvi, je:
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. 
Pri s HIV okuženih bolnikih s hudo imunsko pomanjkljivostjo lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja (CART -"combination antiretroviral therapy") nastane vnetna reakcija na asimptomatične ali rezidualne oportunistične okužbe (glejte poglavje 4.4).
Peripheral blood lymphocytes from AIDS patients receiving zidovudine treatment have also been observed to contain higher numbers of chromosome breakages. 
ki se zdravijo z zidovudinom, so v limfocitih iz periferne krvi opazili večje število lomov kromosomov.
Blood and lymphatic system disorders Common: Anaemia, neutropenia and leucopenia Uncommon: Thrombocytopenia and pancytopenia (with marrow hypoplasia) Rare: Pure red cell aplasia 
Pogosti: anemija, nevtropenija in levkopenija Občasni: trombocitopenija in pancitopenija (s hipoplazijo kostnega mozga)
Therapy should be switched to an alternative regimen if there is suspicion of lipoatrophy development. 
Če obstaja sum, da se razvija lipoatrofija, je treba preiti na drugačno shemo zdravljenja.
Therefore the concomitant use of lamivudine with cladribine is not recommended (see section 4.4) 
Zato sočasna uporaba lamivudina in kladribina ni priporočljiva (glejte poglavje
Lamivudine/zidovudine was shown to be bioequivalent to lamivudine 150 mg and zidovudine 300 mg given as separate tablets, when administered to fasting subjects. 
Teva bioekvivalentno 150 mg odmerku lamivudina in 300 mg odmerku zidovudina danih v ločenih tabletah, če ju bolniki vzamejo na tešče.
A bioequivalence study compared lamivudine/zidovudine with lamivudine 150 mg and zidovudine 300 mg tablets taken together. 
Zdravilo Lamivudin/zidovudin Teva so v raziskavi bioekvivalentnosti primerjali s 150 mg tabletami lamivudina in 300 mg tabletami zidovudina, ki so jih bolniki jemali skupaj.
It is recommended that separate preparations of lamivudine and zidovudine should be administered in cases where dosage adjustment is necessary (see section 4.2). 
V primerih, ko je potrebno odmerek posamezne učinkovine prilagoditi, je priporočljivo uporabiti lamivudin in zidovudin kot samostojni zdravili (glejte poglavje 4.2).
Zidovudine AUC ↑74% (UGT inhibition) 
AUC zidovudina ↑74% (zavrtje UGT)
Zidovudine AUC ↑80% (UGT inhibition) 
AUC zidovudina ↑80% ( zavrtje UGT )
• feeling breathless 
• občutek zadihanosti,
• fever (high temperature) 
• zvišana telesna temperatura,
Not applicable. 
ni podatkov.
Zidovudine and stavudine maintain their antiretroviral activities against lamivudine-resistant HIV-1. 
Zidovudin in stavudin ohranita protiretrovirusno aktivnost na virus
Probenecid/Zidovudine (500 mg four times daily/2 mg/kg thrice daily) 
probenecid/zidovudin (500 mg štirikrat na dan/2 mg/kg trikrat na dan)
Nervous system disorders 
imenovanih nukleozidni zaviralci.
Haematological parameters should therefore be carefully monitored (see section 4.3) in patients receiving Lamivudine/Zidovudine Teva. 
Hematološke parametre je torej potrebno pri bolnikih, ki prejemajo zdravilo Lamivudin/zidovudin
Neither zidovudine nor lamivudine have shown evidence of impairment of fertility in studies in male and female rats. 
V študijah na podganjih samcih in samicah niso ne za zidovudin in ne za lamivudin ugotovili, da bi škodljivo vplivala na plodnost.
• changes in the colour of your nails, your skin or the skin inside your mouth 
• težave z želodcem, motnje okušanja, • spremenjena barva nohtov, kože ali ustne sluznice,
• high doses of co-trimoxazole, an antibiotic. 
• visoki odmerki antibiotika kotrimoksazola;
Rifampicin/Zidovudine (600 mg once daily/200 mg thrice daily) 
rifampicin/zidovudin (600mg enkrat na dan/200 mg trikrat na dan)
Containers: 
Plastenke:
Lamivudine/Zidovudine Teva 150 mg/300 mg film-coated tablets lamivudine/zidovudine 
Lamivudin/zidovudin Teva 150 mg/300 mg filmsko obložene tablete lamivudin/zidovudin
Zidovudine showed clastogenic effects in an oral repeated dose micronucleus test in mice. 
Zidovudin, v ponavljajočih odmerkih peroralno apliciran mišim v okviru mikronukleusnega testa, je imel klastogene učinke.
General disorders and administration site conditions Common: Fatigue, malaise, fever 
Pogosti: utrujenost, splošno slabo počutje, vročica
How to take Lamivudine/Zidovudine Teva Always take this medicine exactly as your doctor or pharmacist has told you. 
Pri jemanju zdravila Lamivudin/zidovudin Teva natančno upoštevajte navodila zdravnika ali farmacevta.
Very common side effects These may affect more than 1 in 10 people: 
Pojavijo se lahko pri največ 1 od 10 bolnikov:
Fluconazole/Zidovudine (400 mg once daily/200 mg thrice daily) 
flukonazol/zidovudin (400 mg enkrat na dan/200 mg trikrat na dan)
Viruses acquire phenotypic resistance to thymidine analogues through the combination of mutations at codons 41 and 215 or by the accumulation of at least four of the six mutations. 
in 215 ali z akumulacijo najmanj štirih od šestih mutacij pridobijo fenotipsko odpornost na analoge timidina.
As dosage adjustment of Lamivudine/Zidovudine Teva is not possible separate preparations of zidovudine and lamivudine should be used. 
Lamivudin/zidovudin Teva prilagajanje odmerka posamezne učinkovine ni možno, je potrebno uporabiti zidovudin in lamivudin kot samostojni zdravili.
There is limited experience of overdosage with lamivudine/zidovudine. 
Izkušnje s prevelikim odmerjanjem zdravila Lamivudin/zidovudin Teva so omejene.
How to store Lamivudine/Zidovudine Teva 
Kako jemati zdravilo Lamivudin/zidovudin Teva
Tablet film-coat Hypromellose 3cP Hypromellose 6cP Polysorbate 80 
hipromeloza 3cP hipromeloza 6cP polisorbat 80 makrogol 400 titanov dioksid (E171)
Macrogol 400 
CD4
Late-onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). 
(hipertonija, konvulzije, nenormalno obnašanje).
The clinical relevance of such findings remains, however, not well defined. 
Vendar pa klinična relevantnost teh odkritij za zdaj še ni dodobra raziskana.
Valproic acid/Zidovudine (250 mg or 500 mg thrice daily/100 mg thrice daily) 
valprojska kislina/zidovudin (250 mg ali 500 mg trikrat na dan/100 mg trikrat na dan)
Package leaflet: Information for the user Lamivudine/Zidovudine Teva 150 mg/300 mg film-coated tablets lamivudine/zidovudine 
Navodilo za uporabo Lamivudin/zidovudin Teva 150 mg/300 mg filmsko obložene tablete lamivudin/zidovudin
MARKETING AUTHORISATION HOLDER 
7 IMETNIK DOVOLJENJA ZA PROMET
Common side effects that might show up in blood tests are: 
Pogosti neželeni učinki, ki se lahko pokažejo v preiskavah krvi, so:
Take special care with Lamivudine/Zidovudine Teva 
Bodite posebno pozorni pri jemanju zdravila Lamivudin/zidovudin Teva
Immune Reactivation Syndrome: In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. 
Sindrom imunske reaktivacije: Pri s HIV okuženih bolnikih s hudo imunsko pomanjkljivostjo lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja (CART - "combination antiretroviral therapy")
When you are being treated for HIV, it can be hard to tell whether a symptom is a side effect of Lamivudine/Zidovudine Teva or other medicines you are taking, or an effect of the HIV disease itself. 
Med zdravljenjem okužbe s HIV, je včasih težko reči ali je simptom neželeni učinek zdravila
• itching 
• driska,
Treatment with Lamivudine/Zidovudine Teva should be stopped immediately if clinical signs, symptoms or laboratory abnormalities suggestive of pancreatitis occur. 
Če klinični znaki, simptomi ali laboratorijska odstopanja kažejo na možnost pankreatitisa, je potrebno zdravljenje z zdravilom Lamivudin/zidovudin Teva nemudoma prekiniti.
Very rare: Aplastic anaemia 
Redki: čista aplazija rdečih krvnih celic Zelo redki: aplastična anemija
• headache • feeling sick (nausea). 
• občutek slabosti (navzea).
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4). 
toda opisani čas do začetka je bolj spremenljiv in ti dogodki se lahko pojavijo veliko mesecev po uvedbi zdravljenja (glejte poglavje 4.4).
• indigestion, taste disturbance 
• slabost (navzea), bruhanje,
• muscle pain and discomfort 
• bolečine v mišicah in neudobje, • bolečine v sklepih,
Nervous system disorders Common: Headache, insomnia Very rare: Peripheral neuropathy (or paraesthesiae) 
Zelo redki: periferna nevropatija (ali parestezija) Bolezni dihal, prsnega koša in mediastinalnega prostora Pogosti: kašelj, nosni simptomi
Dosage in the elderly: No specific data are available, however special care is advised in this age group due to age associated changes such as the decrease in renal function and alteration of haematological parameters. 
zaradi s starostjo povezanih sprememb, kot sta zmanjšano delovanje ledvic in spremembe v hematoloških parametrih, potrebna posebna previdnost pri odmerjanju.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
DATUM ZADNJE REVIZIJE BESEDILA MM/LLLL
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR THE CONTAINER 
PODATKI NA ZUNANJI OVOJNINI ŠKATLA ZA PLASTENKO
Children weighing from 14 kg to 21 kg: the recommended oral dose of Lamivudine/Zidovudine Teva is one-half tablet taken twice daily. 
Otroci s telesno maso od 14 kg do 21 kg: Priporočeni peroralni odmerek zdravila
Lamivudine/Zidovudine Teva contains lamivudine and zidovudine, therefore any interactions identified for these individually are relevant to Lamivudine/Zidovudine Teva. 
Zdravilo Lamivudin/zidovudin Teva vsebuje lamivudin in zidovudin, zato je katerakoli interakcija,
Zidovudine concentrations are increased in patients with advanced renal failure. 
Pri bolnikih z napredovalo odpovedjo ledvic so koncentracije zidovudina povišane.
• stiffness in the joints 
• mravljinčenje v koži,
Skin and subcutaneous tissue disorders Uncommon: Rash and pruritus Rare: Nail and skin pigmentation, urticaria and sweating 
Pogosti: pigmentacija nohtov in kože, urtikarija in znojenje Bolezni mišično-skeletnega sistema in vezivnega tkiva
• drowsiness 
• vrtoglavica,
(often referred to as PCP) 
Pneumocystis Pneumocystis jirovecii (pogosto omenjena kot PCP);
• numbness 
RAZNO
(neutropenia). 
• bruhanje,
Haematological adverse reactions: Anaemia, neutropenia and leucopenia (usually secondary to neutropenia) can be expected to occur in patients receiving zidovudine. 
Neželene hematološke reakcije: Pri bolnikih, ki prejemajo zidovudin se lahko pričakuje pojav anemije,